We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.55 | 1.23% | 45.25 | 44.50 | 46.00 | 45.50 | 45.00 | 45.25 | 178,156 | 08:00:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.23 | 126.78M |
TIDMAVCT
Avacta Group PLC
03 January 2018
For immediate release
3 January 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Presenting at the Biotech Showcase, San Francisco
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Chief Executive Officer, Dr Alastair Smith, will be presenting at the annual Biotech Showcase, 8-10 January 2018, San Francisco.
Dr Smith will outline the key benefits of the Affimer(R) technology as a therapeutic protein platform and update the meeting on progress within the Group's therapeutic programmes.
The presentation will be available on Avacta's website (www.avacta.com).
- Ends -
For further information from Avacta Group plc, please contact:
Hot Features
Premium
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207 220
Geoff Nash / Giles Rolls 0500
- Nominated Adviser www.finncap.com
Tim Redfern / Alice Lane
/ Nikita Jain -
Corporate Broking Tel: +44 (0) 203 705
9318
WG Partners Tel: +44 (0) 203 705
Nigel Birks / Nigel Barnes 9217
David Wilson / Claes Spang www.wgpartners.co.uk
Zyme Communications (Trade Tel: +44 (0)7787 502
and Regional Media) 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Tel: +44 (0)7764 947137
Media and IR) avacta@yellowjerseypr.com
Sarah Hollins
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQLLFBVFFEBBV
(END) Dow Jones Newswires
January 03, 2018 02:00 ET (07:00 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
